BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12357299)

  • 1. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
    Nomata K; Noguchi M; Kanetake H; Tsuda N; Hayashi M; Yamashita S; Sakuragi T; Kusaba Y; Shindo K;
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):266-70. PubMed ID: 12357299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
    Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
    Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
    Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
    Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
    Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ].
    Shichiri Y; Kanba T; Yoshida S; Arai Y
    Hinyokika Kiyo; 1995 May; 41(5):359-64. PubMed ID: 7598036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
    Hinotsu S; Akaza H; Ohashi Y; Kotake T
    Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
    Maekawa S; Suzuki H; Ohkubo K; Aoki Y; Okada T; Maeda H; Ogura K; Arai Y
    Hinyokika Kiyo; 2000 May; 46(5):301-6. PubMed ID: 10876750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.